作为抗癌疗法开发中的药物重定向的纽带,准泛素特异性化酶22 (USP22)
Saad Ali Alshehri1, Abdulrhman Alsayari1, Mohammad Abohassan2
1Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Journal of receptor and signal transduction research
|August 23, 2025
概括
这项研究确定埃尔戈他是一种潜在的重定向药物,可以抑制USP22,这是癌症进展和治疗耐药性的关键目标. 为开发新型癌症治疗方法,建议进行进一步的实验验证.
科学领域:
- 癌症学
- 计算化学
- 药物发现
背景情况:
- 在各种癌症中,尤比特异性酶22 (USP22) 经常过度表达,导致瘤的进展,转移和耐药性.
- USP22在DNA修复,细胞循环调节和癌症干细胞维护等重要细胞过程中发挥着关键作用.
- 对复发性和耐药性USP22过度表达的瘤需要新的治疗策略,使药物重用成为一种有吸引力的方法.
研究的目的:
- 确定FDA批准的药物,可以作为USP22抑制剂重新使用.
- 通过计算选具有高结合亲和度和与USP22结合口袋的特定相互作用的化合物.
主要方法:
- 采用了结合分子对接和分子动力学 (MD) 模拟的集成计算工作流程.
- 从DrugBank中对FDA批准的化合物进行虚拟选.
- 使用全原子MD模拟 (300 ns) 和MM/PBSA计算来评估已识别的化合物的稳定性和结合相互作用.
主要成果:
- 埃尔戈他在USP22结合囊中表现出高结合亲和力和特定相互作用.
- 药物动力学评估表明,埃尔戈他具有适用于抗癌干预的药物特征.
- MD模拟和MM/PBSA分析证实了USP22- ergotamine复合物的稳定性和强度,并提供了对抑制机制的见解.
结论:
- 埃尔戈他具有作为重新定位的USP22抑制剂的显著潜力.
- 作为一种新的癌症治疗药物,需要对埃尔戈他的有效性进行实验验证.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
375
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10.1K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K